Discordant regulation of microRNA between multiple experimental models and human pulmonary hypertension

Chest

Volumn 148, Issue 2, 2015, Pages 481-490

  Schlosser, Kenny ^a   Taha, Mohamad ^a,b   Deng, Yupu ^a   Jiang, Baohua ^a   Stewart, Duncan J ^a,b  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 130B; MICRORNA 145; MICRORNA 17; MICRORNA 204; MICRORNA 21; MICRORNA 424; MICRORNA 503; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CHRONIC DISEASE; CLUSTER ANALYSIS; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; EXPERIMENTAL MODEL; GENE EXPRESSION; GENETIC DISORDER; GENETIC REGULATION; HUMAN; HYPOXIA; MICRORNA BLOOD LEVEL; MICRORNA HEART RIGHT VENTRICLE LEVEL; MICRORNA LUNG LEVEL; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT; RECEIVER OPERATING CHARACTERISTIC; RODENT; SENSITIVITY AND SPECIFICITY; TISSUE LEVEL; ADULT; AGED; ANIMAL; BLOOD; CASE CONTROL STUDY; DISEASE MODEL; FEMALE; GENETICS; HEART VENTRICLE; LUNG; MALE; METABOLISM; MIDDLE AGED; PRINCIPAL COMPONENT ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; ANIMALS; CASE-CONTROL STUDIES; DISEASE MODELS, ANIMAL; FEMALE; HEART VENTRICLES; HUMANS; HYPERTENSION, PULMONARY; LUNG; MALE; MICE; MICRORNAS; MIDDLE AGED; PRINCIPAL COMPONENT ANALYSIS; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84939236016     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.14-2169     Document Type: Article

References (21)

1. Kozomara A, Griffiths-Jones S. miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res. 2014; 42(database issue): D68-D73.
2. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009; 19 (1): 92-105.
3. Jiang Q, Wang Y, Hao Y, et al. miR2Disease: a manually curated database for microRNA deregulation in human disease. Nucleic Acids Res. 2009; 37 (database issue): D98-D104.
4. White K, Loscalzo J, Chan SY. Holding our breath: the emerging and anticipated roles of microRNA in pulmonary hypertension . Pulm Circ. 2012; 2 (3): 278-290.
5. Schermuly RT, Ghofrani HA, Wilkins MR, Grimminger F. Mechanisms of disease: pulmonary arterial hypertension. Nat Rev Cardiol. 2011; 8 (8): 443-455.
6. Pullamsetti SS, Doebele C, Fischer A, et al. Inhibition of microRNA-17 improves lung and heart function in experimental pulmonary hypertension. Am J Respir Crit Care Med. 2012; 185 (4): 409-419.
7. Parikh VN, Jin RC, Rabello S, et al. MicroRNA-21 integrates pathogenic signaling to control pulmonary hypertension: results of a network bioinformatics approach. Circulation. 2012; 125 (12): 1520-1532.
8. Kim J, Kang Y, Kojima Y, et al. An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension. Nat Med. 2013; 19 (1): 74-82.
9. Courboulin A, Paulin R, Giguère NJ, et al. Role for miR-204 in human pulmonary arterial hypertension. J Exp Med. 2011; 208 (3): 535-548.
10. Caruso P, Dempsie Y, Stevens HC, et al. A role for miR-145 in pulmonary arterial hypertension: evidence from mouse models and patient samples. Circ Res. 2012; 111 (3): 290-300.
11. Yang S, Banerjee S, Freitas Ad, et al. miR-21 regulates chronic hypoxiainduced pulmonary vascular remodeling . Am J Physiol Lung Cell Mol Physiol. 2012; 302 (6): L521-L529.
12. Bertero T, Lu Y, Annis S, et al. Systems-level regulation of microRNA networks by miR-130/301 promotes pulmonary hypertension. J Clin Invest. 2014; 124 (8): 3514-3528.
13. Abe K, Toba M, Alzoubi A, et al. Formation of plexiform lesions in experimental severe pulmonary arterial hypertension. Circulation. 2010; 121 (25): 2747-2754.
14. Gupta SK, Bang C, Thum T. Circulating microRNAs as biomarkers and potential paracrine mediators of cardiovascular disease. Circ Cardiovasc Genet. 2010; 3 (5): 484-488.
15. Traill EM. Pulmonary arterial hypertension: an early diagnosis makes a difference . JAAPA. 2011; 24 (5): 30-34.
16. Schlosser K, White RJ, Stewart DJ. miR-26a linked to pulmonary hypertension by global assessment of circulating extracellular microRNAs. Am J Respir Crit Care Med. 2013; 188 (12): 1472-1475.
17. Caruso P, MacLean MR, Khanin R, et al. Dynamic changes in lung microRNA profiles during the development of pulmonary hypertension due to chronic hypoxia and monocrotaline. Arterioscler Thromb Vasc Biol. 2010; 30 (4): 716-723.
18. Maarman G, Lecour S, Butrous G, Thienemann F, Sliwa K. A comprehensive review: the evolution of animal models in pulmonary hypertension research; are we there yet? Pulm Circ. 2013; 3 (4): 739-756.
19. Wei C, Henderson H, Spradley C, et al. Circulating miRNAs as potential marker for pulmonary hypertension. PLoS ONE. 2013; 8 (5): e64396.
20. Peacock AJ, Murphy NF, McMurray JJ, Caballero L, Stewart S. An epidemiological study of pulmonary arterial hypertension . Eur Respir J. 2007; 30 (1): 104-109.
21. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006; 173 (9): 1023-1030.